Current animal models and cell lines used in cancer research do not always accurately replicate human disease. While they provide valuable insights, these models often fail to capture the full complexity of human cancer. This limitation affects the translatability of preclinical findings to human patients, resulting in a high attrition rate for new drugs during clinical trials.
